SC
LEXX icon

Scotia Capital’s Lexaria Bioscience LEXX Stock Holding History

Scotia Capital’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,000
Closed -$21K – 895
2024
Q4 		$21K Buy
+10,000
New +$24.6K ﹤0.01% 844

Other funds holding LEXX

ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
BAM
Byrne Asset Management Kingston, New Jersey $185M AUM 41.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Scotia Capital's LEXX Position: Q1 2025 in Review

Scotia Capital sold out of Lexaria Bioscience (LEXX) in Q1 2025, closing a stake of 10,000 shares — an estimated $21K sold.

Scotia Capital first reported a position in LEXX in Q4 2024 and held it in 1 quarter. The position peaked at $21K in Q4 2024. 22 funds tracked by Wall St. Rank hold LEXX as of Q1 2025.

  • Scotia Capital reported no remaining Lexaria Bioscience position as of Q1 2025 after selling out during the quarter.
  • Scotia Capital sold 10,000 Lexaria Bioscience shares in Q1 2025, an estimated $21K.
  • Scotia Capital first reported a position in Lexaria Bioscience in Q4 2024 and held it in 1 quarter.
  • Scotia Capital's Lexaria Bioscience position peaked at $21K in Q4 2024.
  • 22 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q1 2025.

Based on Scotia Capital's 13F filing for Q1 2025, filed 9 May 2025.